Abbott Laboratories cleared in $1 billion FCA lawsuit

With more than $1 billion in damages on the line, a Texas jury rejected a whistleblower's claims that Abbott Laboratories violated the False Claims Act by improperly marketing bile duct stents, according to FierceMedicalDevices.

 A salesman for Guidant, a company acquired by Abbott in 2006, accused the company of marketing bile duct stents intended for short-term use for complex cases. During the three-week trial, defense attorneys argued that using biliary stents for peripheral vascular or arterial disease was an accepted medical practice. Article

Suggested Articles

The HHS OIG is asking for an additional $23.7 million to support fraud oversight that has benefited from an emphasis on data analytics.

A New York surgeon was sentenced to 13 years in prison for fraud and more physician practice news from around the web.

A federal judge has ruled that the U.S. government’s remaining fraud case against UnitedHealth can move forward.